A detailed history of Wellington Management Group LLP transactions in T Scan Therapeutics, Inc. stock. As of the latest transaction made, Wellington Management Group LLP holds 126,345 shares of TCRX stock, worth $520,541. This represents 0.0% of its overall portfolio holdings.

Number of Shares
126,345
Previous 90,941 38.93%
Holding current value
$520,541
Previous $532,000 18.23%
% of portfolio
0.0%
Previous 0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$4.97 - $7.49 $175,957 - $265,175
35,404 Added 38.93%
126,345 $629,000
Q2 2024

Aug 13, 2024

BUY
$5.85 - $9.51 $532,004 - $864,848
90,941 New
90,941 $532,000
Q4 2021

Feb 11, 2022

SELL
$4.5 - $9.05 $628,047 - $1.26 Million
-139,566 Closed
0 $0
Q3 2021

Nov 15, 2021

BUY
$6.17 - $13.48 $861,122 - $1.88 Million
139,566 New
139,566 $1.16 Million

Others Institutions Holding TCRX

About TScan Therapeutics, Inc.


  • Ticker TCRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 18,929,800
  • Market Cap $78M
  • Description
  • TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell ...
More about TCRX
Track This Portfolio

Track Wellington Management Group LLP Portfolio

Follow Wellington Management Group LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wellington Management Group LLP, based on Form 13F filings with the SEC.

News

Stay updated on Wellington Management Group LLP with notifications on news.